2020/9/25

• Otsuka’s ABILIFY MAINTENA approved for the additional indication of bipolar I disorder in Japan

2020/9/18

• - Creating a Society that Supports Ongoing Employee Health - Full-scale launch of "Kenko Shacho" community website connecting corporate leaders

2020/9/10

• Smart Nutrition for New Lifestyles
  Announcing SOYJOY Green Tea & Macadamia
  Moist Texture Highlights the Mellow Astringency and Savor of Green Tea

2020/9/7

• Otsuka Pharmaceutical Supports High School Students in Summer 2020
  Supporting events across Japan that are close to their hearts, including alternative athletic competitions

2020/9/3

• Top-line Results from Global Phase 3 Program of Vadadustat, a Drug Candidate for Treatment of Renal Anemia due to Chronic Kidney Disease in Non-Dialysis Patients

2020/8/26

• Novartis Pharma and Otsuka to Launch Entresto Tablets in Japan for Patients with Chronic Heart Failure

2020/8/11

• Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag -Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-

2020/7/29

• Otsuka Filed Application in Japan for Approval of Fremanezumab as a Prophylactic Treatment for Migraine

2020/7/8

• Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI, an oral hypomethylating agent (HMA) therapy for MDS and CMML

2020/6/29

• Novartis Pharma obtains manufacturing and marketing approval in Japan for Entresto tablet as angiotensin receptor neprilysin inhibitor (ARNI) for chronic heart failure

2020/6/29

• Samsca approved in Japan for additional indication of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH)

2020/6/29

• Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in CNS indications

2020/6/24

• Clinical program for NY-ESO-1/siTCR gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine

2020/6/19

• Japan's MHLW grants Sakigake Designation to comprehensive genomic profiling assay for hematologic malignancies co-developed by Otsuka

2020/6/16

• Introduction of Set of Heat Disorder-related Teaching Materials: “Get Back That Sweat! Preventing Heat Disorders Together”

2020/6/16

• Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE Combination Ophthalmic Suspension

2020/6/12

• Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients

2020/5/25

• Deltyba (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)

2020/5/22

• Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: “Cabpirin® Combination Tablets”

2020/5/5

• Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

2020/4/27

• Otsuka Pharmaceutical to use CO2-free electricity at all plants in Japan

2020/4/24

• Research on the Relationship Between Hair Problems and Capacity to Produce Equol

2020/4/20

• Otsuka Enters into Licensing Agreement in Japan for Bempedoic Acid, a Treatment for Hypercholesterolemia

2020/4/1

• Otsuka to Introduce QuickNavi-Adeno2, an Adenovirus Quick Measurement Kit
  - Faster and clearer test results with two contrasting colors -

2020/3/26

• Development of the first comprehensive genomic profiling assay for hematologic malignancies in Japan
  - Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a project to evaluate its clinical utility -

2020/3/26

• Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug Candidate Difamilast (OPA-15406)

2020/3/25

• Otsuka’s Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma

2020/3/25

• Cabpirin Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin

2020/3/16

• Dietary Education App "SketchCook"
  Recognized with Ministry of Education, Culture, Sports, Science and Technology（MEXT）
  "Award for Companies Promoting Experience-based Learning Activities for Youth 2019"

2020/3/13

• Newly published findings on inhibitory effect of near-infrared (IRA) radiation on human epidermal cell proliferation and potential mechanisms

2020/3/10

• Otsuka Pharmaceutical Reappointments and New Appointments of Board Members and Statutory Auditors

2020/3/3

• Introducing InnerSignal Rejuvenate ONE
  —All-in-One Skin Care Product with Time-Lapse Penetration Combines Lightening and Three Basic Skin Care Functions—

2020/3/2

• Otsuka Pharmaceutical enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan

2020/2/27

• First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis

2020/2/27

• Introducing New UL・OS AMP Face & Body Sheet for Skin A single sheet provides convenient facial and body care

2020/2/27

• Otsuka Pharmaceutical Establishes Subsidiary in Malaysia

2020/2/26

• Launch of “Health Support Plus”
  Service to manage workforce health based on desknet’s NEO groupware

2020/2/25

• Whole soy nutrition bar delivers the same satisfying crunchy texture with a significant reduction in sugars
  SOYJOY Peanuts Renewal Launch
  

2020/2/14

• Otsuka Pharmaceutical and the Japan Kidney Association Form Collaborative Agreement

2020/2/12

• Otsuka announces that subsidiary Astex Pharmaceuticals’ NDA for ASTX727 (oral C-DEC), for the treatment of MDS and CMML, has been accepted for priority review by the U.S. FDA

2020/2/6

• Tokyo Marathon 2020 - Connecting With the World Otsuka Pharmaceutical to be an Official Partner for 14th consecutive year

2020/1/31

• Otsuka Pharmaceutical Establishes Health Beverage Subsidiary in Mexico

2020/1/27

• Otsuka announces positive top-line results from clinical trials in Japan of fremanezumab as a prophylactic treatment for migraine

2020/1/21

• Otsuka enters multi-project drug discovery collaboration with PhoreMost Limited

2019/12/11

• Announcement of Changes in Company Officers at Otsuka Pharmaceutical Co., Ltd.

2019/12/9

• Senju and Otsuka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA Combination Ophthalmic Solution

2019/11/28

• POConePlus Infrared Spectrophotometer for Diagnosis of H. pylori infection launched in Japan

2019/11/27

• Construction Completed on Otsuka's New Pharmaceutical Factory Plant in Mima City, Tokushima Prefecture, Japan

2019/11/27

• Otsuka Launches New SAMSCA Formulation in Japan: SAMSCA OD Tablets

2019/11/18

• Otsuka Pharmaceutical Cosponsors "Asan Walking Festa in Itano" as Part of Community Health Promotion Efforts

2019/11/12

• Otsuka Pharmaceutical and Avanir Pharmaceuticals to Continue Clinical Development of Investigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia

2019/10/16

• RS Virus Rapid-measurement Kit Quick Navi-RSV2 To Be Launched in Japan
  　Faster test results and enhanced visual features with two color lines

2019/10/15

• Presentation of Effects of Lactic Acid Bacteria B240 at Palynological Society of Japan

2019/10/1

• Three New Flavors of Easy-to-Drink Balanced Nutrition Beverage Introducing Calorie Mate Liquid

2019/9/27

• Otsuka's Subsidiary Avanir Pharmaceuticals Reports Top-line Data from Second Phase 3 Trial Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia

2019/9/26

• Otsuka Applies for the Additional Indication in Japan of Bipolar Disorder for ABILIFY MAINTENA for Suspended Release Injectable Suspension

2019/9/26

• New Series Expands the SOYJOY Line of Whole Soy Nutrition Bars SOYJOY Scone Bar Plain

2019/9/20

• Otsuka Pharmaceutical Greenhouse Gas Emissions Reduction Targets Earn Science Based Targets (SBT) Initiative Certification

2019/9/13

• Otsuka Pharmaceutical Enters Into Cooperative Agreement with Niigata Prefecture to Support Prefectural Residents’ Health Promotion Project

2019/8/28

• Approval for the Additional Formulation of SamscaR OD Tablets in Japan

2019/8/23

• UL•OS Men's Skincare Brand
  Renewal Launch of Three Moisturizing Products

2019/8/19

• Otsuka Pharmaceutical Participates in Summer Events in Tokushima, Japan Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink PRESENTS Awa Odori Sound Festival

2019/7/22

• Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Nagano Prefecture

2019/6/28

• POCARI SWEAT Marketing Wins Top Prize at Japan Marketing Awards

2019/6/28

• Deliciously Illustrated SketchCook
  Wins in Three Categories at PR Awards Asia 2019 ― Dietary education app promotes awareness about the importance of meals and nutrition to children―

2019/6/7

• Otsuka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals’ Drug Candidates in North America

2019/6/7

• Otsuka and its Subsidiary Astex Pharmaceuticals, Inc. Announce Positive Results from a Phase III Clinical Trial of Anticancer Aandidate ASTX727

2019/5/22

• Otsuka and Japan Kidney Association to Collaborative on Autosomal Dominant Polycystic Kidney Disease

2019/4/18

• BALVERSA™ (erdafitinib) Receives Regulatory Approval in U.S.

2019/4/12

• EQUELLE: Dietary Supplement to Support Women's Health Expansion of US business through launch of sales via D-to-C channel

2019/4/8

• Otsuka Pharmaceutical Establishes Health Beverage Subsidiary in Myanmar

2019/3/28

• Otsuka Pharmaceutical to Sponsor 30th Southeast Asian Games 2019 (Philippines)

2019/3/25

• Otsuka’s Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer’s Dementia

2019/3/11

• Notice regarding the conclusion of co-development/co-promotion activities in Japan for the anti-epileptic drug "E Keppra"

2019/3/7

• Otsuka Pharmaceutical Reappointments and New Appointments of Board Members and Statutory Auditors

2019/3/5

• Selincro Tablets 10mg Launched in Japan

2019/2/27

• Refreshing Men’s Facial Lotion for Summer Comfort Introducing UL・OS Medicated Skin Breezy Lotion A single product to moisturize, minimize oily shine, and prevent formation of blemishes

2019/2/19

• Otsuka Pharmaceutical to Serve as an Official Partner for Tokyo Marathon 2019 New “Run,” “Support,” “Boost,” Program Benefits All Participants

2019/2/15

• Otsuka and Lundbeck report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder

2019/2/14

• Designation Description Change of NY-ESO-1・siTCRTM gene therapy product under “SAKIGAKE Designation System”

2019/2/13

• Avanir Pharmaceuticals, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA (dextromethorphan HBr and quinidine sulfate) 20 mg/10 mg capsules

2019/2/4

• Introducing SOYJOY Crispy Sakura
  Special Seasonal Flavor from SOYJOY Brand of Whole Soy Nutrition Bars
  

2019/1/8

• Selincro (nalmefene) Tablets 10mg Receives Regulatory Approval in Japan

2019/1/4

• Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder

2018/12/11

• Otsuka subsidiary Avanir and Optinose agree to terminate license agreement for migraine treatment ONZETRA®Xsail®

2018/11/30

• Otsuka and Lundbeck report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)

2018/10/15

• Quick Navi-Reader for Diagnosis of Influenza to be Launched in Japan

2018/10/11

• Otsuka and Proteus Digital Health Announce Expanded Collaboration Agreement to Advanced Digital Medicines for Mental Health

2018/10/1

• Launch of Nationwide Retail Distribution of “Barrier Beverage” BODYMAINTÉ Drink

2018/9/25

• Busulfex Injection 60mg Approved in Japan for Once-Daily Administration in Adults

2018/9/3

• Otsuka Pharmaceutical Cooperates with Community Health Promotion Efforts Tokushima Itano Factory Sponsors “Asan Walking Festa in Itano”

2018/8/21

• Osaka University and Otsuka Pharmaceutical to Enter into an Executive Licensing Agreement on Novel "CAR-T Cell Therapy" for Multiple Myeloma

2018/8/15

• Otsuka Pharmaceutical Participates in Summer Events in Tokushima
  Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink PRESENTS Awa Odori Sound Festival
  

2018/7/31

• Otsuka and Lundbeck’s Rxulti® (brexpiprazole) approved by the European Commission

2018/7/31

• Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy

2018/7/12

• Focus on Core Temperature as a Heat Disorder Countermeasure
  - New POCARI SWEAT ICE SLURRY "Cools from the Core"

2018/7/11

• Otsuka Pharmaceutical to Acquire Visterra

2018/7/5

• Launch of SOYJOY
  Manufacturing and Marketing in Indonesia

2018/7/2

• Expansion of Overseas Marketing of POCARI SWEAT ION WATER July 2018 Marks Official Launch in Singapore

2018/6/4

• Otsuka and Lundbeck’s Rxulti® (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults.

2018/6/1

• ORONAMIN C DRINK Makes a Debut in Indonesia

2018/5/28

• Luscious peach flavor evokes a summery mood – New SOYJOY Crispy Peach

2018/5/24

• Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease

2018/5/23

• Otsuka Pharmaceutical Establishes Subsidiary in Singapore

2018/5/18

• May 18 Launch of “Deliciously Illustrated Sketch Cook”
  Children’s cooking illustrations transformed into vivid images and recipes in an entertaining dietary education app using state-of-the-art AI technology to teach

2018/4/25

• Otsuka’s JYNARQUE (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)

2018/4/18

• REXULTI® Tablets, a New Antipsychotic Drug, Launched in Japan

2018/4/9

• Otsuka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies

2018/3/30

• Introducing EQUELLE Gelée, a Flavorful and Convenient Supplement from the EQUELLE Brand – Supports women’s beauty and health from the inside out –

2018/3/28

• Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Tottori Prefecture

2018/3/26

• Otsuka Pharmaceutical Enters Into Comprehensive Regional Revitalization Partnership with Kyoto Prefecture

2018/3/23

• Otsuka's DELTYBA Approved in China for the Treatment of Multidrug-resistant Tuberculosis

2018/3/7

• Otsuka Pharmaceutical Appoints Board Members and Statutory Auditors

2018/3/5

• New addition to SOYJOY line of soy snack bars
  - SOYJOY Crispy Banana -
  

2018/2/27

• New EQUELLE Gelée Supports the Fundamentals of Women’s Beauty and Health - New from the trusted EQUELLE brand, a flavorful, convenient equol supplement -

2018/2/21

• Otsuka Pharmaceutical Certified for Two Years in a Row as Excellent Health and Productivity Management Enterprise

2018/2/9

• Otsuka Pharmaceutical Serves as Official Partner for Tokyo Marathon 2018
  - Helping Runners Give Their Best Performance for 12th Consecutive Year –

2018/1/29

• Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
  

2018/1/22

• Otsuka Introduces Conditioning Drink Version of BODYMAINTÉ

2018/1/19

• Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti Tablets for Schizophrenia

2018/1/10

• Acquisition of BC BIO, French Organic Food Product Manufacturer -European subsidiary seeks to reinforce offering of organic food products–

2017/12/25

• Otsuka and DKSH to commence sales of Otsuka prescription drugs in Myanmar

2017/12/25

• Otsuka to Invest in Megakaryon Corporation、with the Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations

2017/12/20

• Otsuka and X-Chem Enter into a Drug Discovery Research
  and License Collaboration
  

2017/12/19

• Otsuka Pharmaceutical Establishes Joint Research Chair for Women’s Health Promotion with Hirosaki University Graduate School of Medicine

2017/12/14

• Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time

2017/12/13

• Otsuka Pharmaceutical Unveils It’s Completely New Website

2017/12/12

• Otsuka Pharmaceutical Receives Newly Established “Sports Yell Company” Certification from Japan Sports Agency

2017/12/8

• Observational study of 88 female Kindai University athletes
  Relationship between premenstrual syndrome-induced interference in athletic performance and equol production status

2017/11/29

• Otsuka Pharmaceutical to Launch New, Pre-mixed Flavor Formulations (Fruit and Coffee) for Aminoleban EN, an Oral Nutritional Supplement for Patients with Liver Failure

2017/11/29

• Otsuka Pharmaceutical Launches New Formulations in Japan of L-Cartin for Carnitine Deficiencies

2017/11/21

• Otsuka Pharmaceutical Enters Into Comprehensive Regional Revitalization Partnership Agreement with Yamaguchi Prefecture

2017/11/20

• 
  Otsuka Pharmaceutical Cooperates with Community Health Promotion Efforts Tokushima Itano Factory Sponsors “Asan Walking Festa in Itano”

2017/11/15

• Otsuka Pharmaceutical to Become a Sponsor of the 18th Asian Games

2017/11/14

• Otsuka and Proteus Announce the First U.S. FDA Approval of a Digital Medicine System:
  ABILIFY MYCITE (aripiprazole tablets with sensor)
  

2017/11/9

• U.S. FDA Accepts Otsuka’s Resubmission to Support a Regulatory Review of Tolvaptan in the Treatment of ADPKD

2017/11/8

• Otsuka Pharmaceutical Enters into Comprehensive Cooperative Partnership with Oita Prefecture

2017/11/6

• Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

2017/11/2

• Otsuka Pharmaceutical Tokushima Wajiki Factory Receives
  2017 Minister of Economy, Trade and Industry Award for Excellent Greening, a First for the Shikoku Region

2017/11/1

• Otsuka and Lundbeck will Initiate a Third Phase 3 Trial to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

2017/10/31

• US Launch of EQUELLE, a Dietary Supplement to Support Women’s Health

2017/10/25

• Heat Disorders Prevention - Communication Project “Hitosuzumi Awards 2017”
  Otsuka Pharmaceutical Recognized with “Team Excellence” and “Top Runner” Awards
  

2017/10/17

• Otsuka Submits a Japan NDA for Nalmefene, a Drug to Reduce Alcohol Consumption in Alcohol-Dependent Patients

2017/10/12

• Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder

2017/10/10

• Otsuka Pharmaceutical Enters into Comprehensive Partnership with Kochi Prefecture

2017/9/13

• Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Ehime Prefecture

2017/8/24

• Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba™) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries

2017/8/21

• Extremely Fine-textured Foam Facial Cleanser
  Introducing UL•OS Face Wash for Skin Care
  Evolution of Face Wash from “Cleansing” to “Skin Care”

2017/8/15

• Otsuka Pharmaceutical Participates in Summer Events in Tokushima Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink Presents Awa Odori Sound Festival

2017/7/29

• ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder

2017/7/28

• Otsuka Submits New Drug Application in Japan
  for Aripiprazole Sertraline Combination Tablets

2017/7/27

• Otsuka Pharmaceutical to Acquire Daiya, a Rapidly Growing Plant-Based Food Company in North America

2017/7/25

• Otsuka Pharmaceutical Serves as Special Sponsor of Summer Inter-High School Athletic Meeting for Fourth Consecutive Year
  Event Venue Enlivened with Heat Stroke Prevention Posters and Banners Submitted by Local High School Students

2017/7/24

• “Quick Navi-Flu2” Influenza Diagnostic Kit to Launch in Japan

2017/7/20

• Otsuka Pharmaceutical Enters into Partnership Agreement with Wakayama Prefecture

2017/7/18

• Otsuka Pharmaceutical Establishes New Functional Food and Beverage Affiliate in Thailand

2017/7/18

• Otsuka and R-Pharm Announce Licensing Agreement to Commercialize Deltyba™ (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries

2017/7/12

• Smart Medicine Container for Anti-stroke Medicine Approved for Sale in Japan

2017/6/8

• Nalmefene, a Drug Candidate to Reduce Alcohol Consumption, Shows Positive Results from Phase III Trial in Japan

2017/6/8

• Quick Navi – Mycoplasma Diagnostic Kit to Launch in Japan

2017/6/1

• Otsuka to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)

2017/5/30

• Additional Formulation of Samsca® Granules 1% Available in Japan

2017/5/29

• Kenja-no-Kaimin Sleep Rhythm Support
  Asparagus-derived ingredient improves sleep-wake rhythms and enhances quality of sleep

2017/5/23

• Otsuka and Proteus Digital Heath Resubmit Application to US FDA for First Digital Medicine

2017/5/22

• Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S.

2017/5/15

• Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab
  (TEV-48125)

2017/5/15

• Otsuka Agree to Purchase New Share Allocation of TWO CELLS

2017/5/15

• Otsuka Pharmaceutical Announces Construction of New Pharmaceutical Manufacturing Facility, Tokushima Mima Factory

2017/5/11

• Nutrition & Santé Inaugurates New Gluten-Free Manufacturing Facility

2017/5/2

• Otsuka and Lundbeck announce results of brexpiprazole on symptoms of agitation related to Alzheimer's-type dementia

2017/4/26

• Otsuka and Akebia Concludes Licensing Agreement for Akebia’s Renal Anemia Drug Vadadustat
  - Development and marketing territories include Europe, China, etc. -

2017/4/14

• Renewal of Fibe-Mini Dietary Fiber Beverage Food for Specified Health Uses Now Contains Lycopene
  - Renewal Launch with New Package and Logo Design -

2017/4/4

• Amino-Value 4000 and Amino-Value Powder 8000 Renewed as Foods with Function Claim “Alleviates Fatigue Caused by Physical Activity”

2017/4/3

• Otsuka Pharmaceutical Introduces New BODYMAINTÉ Brand BODYMAINTÉ Jelly, a conditioning food to be launched in April 2017

2017/3/27

• Otsuka Pharmaceutical Enters into Health-related Partnership with Fukui Prefecture

2017/3/24

• Otsuka Pharmaceutical Enters into Comprehensive Partnership Agreement with Ibaraki Prefecture

2017/3/23

• Ribociclib (LEE011) Receives Regulatory Approval in U.S. as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor

2017/3/16

• Approval for the Additional Formulation of Samsca® Granules 1% in Japan

2017/3/7

• Otsuka Pharmaceutical Appoints Board Members and Statutory Auditors

2017/3/3

• Otsuka Supports "Light-Up in Green" Glaucoma Awareness Activities

2017/3/3

• Otsuka Pharmaceutical to Acquire Neurovance, Inc.
  Acquisition of clinical-stage company in ADHD widens Otsuka's presence in mental health

2017/2/28

• New Addition to Gerblé Line of Nutritional Food Products from Southern France
  - Prune & Fig Biscuits -

2017/2/24

• Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Tochigi Prefecture

2017/2/22

• Otsuka Pharmaceutical Certified as Excellent Health and Productivity Management Enterprise

2017/2/21

• Otsuka Pharmaceutical Introduces New BODYMAINTÉ Brand BODYMAINTÉ Jelly, a conditioning food to support athletic performance　to be launched in April 2017

2017/2/20

• Otsuka Launches OATHAS Training Program for Healthy Aging Supporters Program to support pharmacies as health information bases with strong connections to local community

2017/2/20

• Health Canada Approves Otsuka and Lundbeck's REXULTI (brexpiprazole) as a Treatment for Schizophrenia in Adults

2017/2/16

• Otsuka Pharmaceutical Supports Tokyo Marathon 2017 as Official Partner Providing comprehensive support for runners’ conditioning for the 11th consecutive year

2017/2/16

• Osaka University and Otsuka Agree Comprehensive Collaboration:
  Joint Research Project with Immunology Frontier Research Center (IFReC)

2017/2/14

• Otsuka Pharmaceutical Enters into Comprehensive Partnership with Okinawa Prefecture

2017/2/10

• Otsuka Pharmaceutical Enters into Comprehensive Health-related Agreement with Aichi Prefecture

2017/2/3

• Otsuka Pharmaceutical Enters into Health Promotion and Disaster Relief Supply Agreements with Kagawa Prefecture

2017/2/3

• Introducing New SOYJOY Crispy White Macadamia Crunchy soy nutrition bar flavored with soy-based white chocolate and macadamia nuts

2017/1/31

• Otsuka Pharmaceutical Enters into Health Promotion Partnership with Chiba Prefecture

2017/1/27

• Otsuka Files a Supplemental Application in Japan:
  A Plastic Case with Anti-Stroke Medicine for a Smart Medicine Container
  

2017/1/26

• Blocks both Ultraviolet and Near Infrared Radiation Announcing New InnerSignal UV+IR Protect Makeup Base

2017/1/26

• Blocks both Ultraviolet and Near Infrared Radiation Announcing New InnerSignal UV+IR Protect Makeup Base

2017/1/24

• Hokkaido University and Otsuka Pharmaceutical to
  Collaborate in Joint Research
  - New Food Research Section Established within Hokkaido University Institute for Promotion of Business-Regional Collaboration -

2017/1/24

• Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Shimane Prefecture

2017/1/11

• Otsuka Launches a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna® Combination Ophthalmic Solution in Japan

2017/1/6

• Otsuka Submits New Drug Application in Japan for Brexpiprazole in the Treatment of Schizopherenia

2016/12/21

• Otsuka Pharmaceutical Enters into Health Promotion Partnership with Gunma Prefecture

2016/12/20

• Akebia Therapeutics and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.

2016/12/15

• Otsuka Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational Cancer Treatment HF10, an Oncolytic Virus

2016/12/5

• Otsuka Pharmaceutical Enters into Comprehensive Cooperative Partnership with Nara Prefecture

2016/12/1

• FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena® (aripiprazole) For The Treatment Of Bipolar I Disorder

2016/11/21

• Otsuka Pharmaceutical Cooperates with Community Health Promotion Efforts Tokushima Itano Factory Sponsors Asan Walking Festival in Itano

2016/11/18

• New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available in Japan

2016/11/18

• ICLUSIG Tablets 15 mg Now Available in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

2016/11/10

• Relationship between PMS/PMDD and production status of soy isoflavone metabolite equol Presentation to the Japan Society for Menopause and Women’s Health

2016/11/1

• Otsuka Pharmaceutical Enters into Comprehensive Partnership with Hyogo Prefecture

2016/10/31

• Heatstroke Prevention Communication Project Hitosuzumi Awards 2016 Otsuka Pharmaceutical Named “Best Communicator” for Third Consecutive Year Proactive Efforts to Raise Awareness Also Recognized with “Top Runner Award”

2016/10/28

• Pocari Sweat Recognized with Good Design Long Life Design Award

2016/10/28

• ORONAMIN C DRINK Recognized with Good Design Long Life Design Award

2016/10/19

• Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka’s Subsidiary Astex Pharmaceuticals

2016/10/18

• Otsuka Pharmaceutical Enters into Disaster Support Agreement with Fukui Prefecture

2016/9/28

• ICLUSIG® Tablets 15 mg Approved in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

2016/9/28

• Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder

2016/9/28

• Otsuka receives approval in Japan for Mikeluna® combination ophthalmic solution, a new treatment for glaucoma and ocular hypertension

2016/9/26

• Headline conclusions from the phase III study of idalopirdine (Lu AE58054) for cognitive symptoms associated with Alzheimer’s disease

2016/9/26

• U.S. FDA Approves Labeling Update of REXULTI®(brexpiprazole) for Maintenance Treatment of Schizophrenia in Patients in the U.S.

2016/9/15

• Otsuka Pharmaceutical Enters into Health Promotion Partnership with Yamanashi Prefecture

2016/9/14

• Announcement of Co-promotion of New Glaucoma Treatment

2016/9/7

• Otsuka and NEC agree to develop a smart medicine container to assist patients in taking daily anti-stroke medication at the appropriate time

2016/9/7

• Otsuka Pharmaceutical Enters into Partnership Agreement with Yamagata Prefecture, Aiming to Achieve Japan’s Top Healthy Life Expectancy

2016/9/2

• Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Kanagawa Prefecture

2016/9/1

• Otsuka Pharmaceutical Enters into Comprehensive Health Promotion Partnership with Kumamoto Prefecture

2016/9/1

• RIKEN CDB-Otsuka Pharmaceutical Collaboration Center launches
  --Aims to create new values by integrating original research--

2016/8/31

• Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Toyama Prefecture

2016/8/16

• Otsuka Pharmaceutical Participates in Summer Events in Tokushima Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink Presents Awa Odori Sound Festival

2016/8/9

• Otsuka Pharmaceutical Enters into Health Promotion Partnership with Miyagi Prefecture

2016/7/13

• Otsuka Pharmaceutical Enters into Comprehensive Partnership with Shizuoka Prefecture

2016/7/8

• Otsuka Pharmaceutical Enters into Health Promotion Partnership with Gifu Prefecture

2016/7/5

• ORALTAG (iohexol), a New Oral Contrast Agent for Abdominal CT Scans, Launched in U.S.

2016/6/29

• Otsuka Pharacemutical Enters into Comprehensive Partnership with Miyazaki Prefecture

2016/6/27

• Otsuka Pharmaceutical Donates Funds for a Sub Rural Health Center in Myanmar For the stable provision of maternal and child health services

2016/6/14

• Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.

2016/6/13

• Otsuka Pharmaceutical and IBM Japan to Set Up Joint Venture for Digital Health Solutions in Central Nervous System Field

2016/6/7

• VONOSAP® pack 400, VONOSAP® pack 800 and VONOPION® pack (triple-drug blister packs containing TAKECAB® tablet) Now Available for Helicobacter pylori* Eradication in Japan

2016/5/30

• Otsuka Pharmaceutical Enters into Health Promotion Partnership Agreement with Akita Prefecture

2016/5/26

• Thirst-quenching support for optimum day-to-day condition Introducing New POCARI SWEAT Ion Water Powder (to make 750ml)

2016/5/25

• Otsuka Pharmaceutical Enters into Health Promotion Partnership with Fukushima Prefecture

2016/5/25

• "Neupro Patch", a Dopaminergic, Anti-Parkinsonian Drug, Will Become Available in Japan in an Additional New Dosage, “Neupro Patch 18 mg”

2016/5/24

• Otsuka Pharmaceutical Enters into Health Promotion Partnership with Nagasaki Prefecture

2016/5/19

• Otsuka Pharmaceutical to Support Japan’s COOL CHOICE Movement Cooperation in Public Awareness Campaigns to Encourage Wise Decisions to Counteract Global Warming

2016/5/13

• Otsuka Pharmaceutical Enters Into
  Comprehensive Partnership Agreement with Osaka Prefecture

2016/5/9

• Introducing Three New Flavors of Calorie Mate Jelly Focusing on the Need for a Nutritionally Balanced Jelly Beverage Option

2016/4/27

• FDA Issues Complete Response Letter For Digital Medicine New Drug Application

2016/4/26

• Otsuka Pharmaceutical Enters into Health Promotion Partnership with Kagoshima Prefecture

2016/4/22

• Otsuka Pharmaceutical Enters into Comprehensive Partnership with Mie Prefecture

2016/4/21

• Otsuka receives two commendations by the Japanese Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment

2016/4/20

• Otsuka’s U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia

2016/4/12

• Otsuka Pharmaceutical Launches “POCARI SWEAT & TOKYO Project” in Cooperation with Tokyo Metropolitan Government

2016/4/4

• New POCARI SWEAT Jelly for “Edible Hydration”
  First new form of POCARI SWEAT since initial launch 36 years ago

2016/4/1

• Thirst-quenching beverage aims to help women maintain optimum day-to-day condition Renewed Version of POCARI SWEAT Ion Water

2016/3/31

• Otsuka Pharmaceutical Signs Health Promotion Support Agreement with Hyogo Prefecture

2016/3/30

• Otsuka Pharmaceutical Enters Into Comprehensive Partnership with Hiroshima Prefecture

2016/3/28

• Otsuka Pharmaceutical Enters into Disaster Relief Supply Agreement with Ishikawa Prefecture

2016/3/16

• Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Okayama Prefecture

2016/3/15

• New casual soy bar with the pleasant crunchy texture of puffed soy “SOYJOY Crispy” Debuts in Three Flavors

2016/3/11

• Otsuka Pharmaceutical Supports 37,000 Runners with Nutritional and Rehydration Products and Cadre of Blue Volunteers at Tokyo Marathon 2016

2016/3/8

• Otsuka Pharmaceutical Co., Ltd. Appoints Board Members and Statutory Auditors

2016/3/2

• ABILIFY for Extended Release Injectable Suspension, Used to treat Schizophrenia, Has Received Approval in Japan for Administration at Deltoid Muscle Site

2016/2/29

• Anti-epileptic Drug E Keppra (generic name: levetiracetam) Obtains Additional Indication of Adjunctive Therapy for Generalized Tonic-Clonic Seizures in Japan

2016/2/26

• Takeda Obtains New Drug Application Approval for Helicobacter pylori Eradication triple-drug Blister Packs Containing TAKECAB tablet, “VONOSAP® pack 400”, “VONOSAP® pack 800” and “VONOPION® pack” in Japan

2016/2/25

• Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility

2016/2/22

• Otsuka Pharmaceutical Enters Partnership Agreement with Aomori Prefecture on Health Literacy Enhancement

2016/2/19

• Otsuka Pharmaceutical to Support Japan Anti-Doping Agency’s Official Sports Pharmacist Certification System

2016/2/19

• Otsuka Pharmaceutical Enters Into Comprehensive Health Promotion Partnership with Tokushima Prefecture

2016/2/9

• Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in the U.S. for Atopic Dermatitis

2016/1/29

• Otsuka’s Subsidiary Avanir Pharmaceuticals Announces U.S. FDA Approval of ONZETRA Xsail for the Acute Treatment of Migraine in Adults

2016/1/26

• Otsuka Pharmaceutical Forms Joint Venture Company for Functional Food and Beverages in the Philippines

2016/1/13

• Otsuka Pharmaceutical Enters Into Comprehensive Health Promotion Partnership with Iwate Prefecture

2016/1/8

• Otsuka and ARIAD Announce New Drug Application for Ponatinib Submitted in Japan for the Treatment of Refractory Leukemia

2015

2015/12/21

• Otsuka Pharmaceutical Concludes Comprehensive Agreement with Shiga Prefecture

2015/12/7

• Winner Announced for the 2015 Young Innovator in TB Research Award

2015/12/7

• Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism

2015/12/1

• POCARI SWEAT Launched in Cambodia on December 1, 2015

2015/11/26

• E Keppra® Injectable, to be Launched in Japan on December 1; Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged 4 and Over with Partial-onset Seizures

2015/11/17

• Otsuka Pharmaceutical Affiliate Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer’s Disease

2015/11/16

• Nature Made Ginkgo Biloba
  Otsuka Pharmaceutical Introduces Japan’s First Food with Specific Function Claim for Cognitive Functions

2015/11/16

• 10,000 Attend 7th Asan Walking Festival in Itano on November 15 Cosponsored by Otsuka Pharmaceutical Tokushima Itano Factory

2015/10/7

• Acquisition of BIOCENTURY,
  Leading Spanish Health and Functional Food Company

2015/10/1

• New Drug Application for Carteolol Hydrochloride/ Latanoprost , a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension

2015/9/11

• U.S. FDA Accepts First Digital Medicine New Drug Application for Otsuka and Proteus Digital Health

2015/9/3

• Three New SOYJOY Bars, Enhanced with More Fruit, More Flavor Raisin, Apple and Hawthorn Berry

2015/8/27

• Three Nature Made Products Receive Foods with Function Claims
  Labels specify benefits for eyes and inhibition of triglyceride levels in the blood

2015/8/27

• Omugi Gohan Barley Rice from OMUGI SEIKATSU Receive Food with Function Claims
  Labels specify three benefits, including control of glucose absorption

2015/8/13

• Otsuka Pharmaceutical’s Subsidiary Avanir Pharmaceuticals Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026 in the U.S.

2015/8/6

• New Pen-type UL•OS Medicated Skin Whitening Helps Men Avoid Dark Spots and Freckles by Inhibiting Melanin Formation

2015/7/29

• Otsuka Pharmaceutical’s Subsidiary Astex Enters New Consortium for Drug Discovery Research at the University of Cambridge

2015/7/16

• Efficacy Results of Otsuka’s Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine

2015/7/13

• U.S. FDA Approves Otsuka and Lundbeck’s REXULTI; (brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia

2015/7/1

• Otsuka Pharmaceutical Continues the Overseas Distribution Expansion of POCARI SWEAT East Timor Market Official Launch July 1, 2015

2015/6/24

• Otsuka Pharmaceutical Enters Into Health Promotion Partnership Agreement with Saitama Prefecture

2015/6/23

• Renovation of POCARI SWEAT Factory at Tianjin Otsuka Beverage Co., Ltd.
  Visitor-friendly Factory Conveys the Importance of Ions and Fluid Replenishment

2015/5/28

• Otsuka’s JINARC® the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease

2015/5/20

• Overseas Distribution of ORONAMIN C DRINK Expands to Hong Kong

2015/5/20

• New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launched on May 25

2015/4/23

• Kenja-no-shokutaku Double Support
  Makes Overseas Debut in Hong Kong

2015/4/20

• Results of Phase III Study of Brexpiprazole in Adult Patients with Schizophrenia Published in American Journal of Psychiatry

2015/4/7

• Review of research on use by menopausal women of nutritional supplement equol appears in US women’s health publication

2015/4/1

• A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Otsuka’s Major BCR-ABL mRNA Measurement Kit Covered by Health Insurance in Japan as of April 1

2015/3/30

• Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in the Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)

2015/3/26

• Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY – ABILIFY for Extended–release Injectable Suspension, for Intramuscular Use – Indicated for Schizophrenia

2015/3/26

• Novel Anti-epileptic Drug E Keppra Filed in Japan for Additional Indication of Adjunctive Therapy for Generalized Tonic-clonic Seizures

2015/3/26

• New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan

2015/3/19

• The Union and Otsuka Open Nominations for
  2nd Global TB Research & Innovation Award

2015/3/18

• Celebrating 50 Years of ORONAMIN C DRINK

2015/3/10

• New SOYJOY With More Fruit!
  Renewed Strawberry and Blueberry Versions Contain More Fruit

2015/3/6

• Otsuka Pharmaceutical Co., Ltd. Appoints Board Members and Statutory Auditors

2015/3/2

• CHMP RECOMMENDS JINARC® (TOLVAPTAN) FOR APPROVAL IN EU:
  THE FIRST PHARMACEUTICAL TREATMENT FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

2015/3/2

• Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area

2015/3/2

• Otsuka Pharmaceutical, Otsuka Wellness Vending and Asahi Soft Drinks Form Business Partnership for Vending Machine Sales

2015/2/27

• First-ever treatment approved in Canada for adults living with ADPKD, a life-threatening kidney disease

2015/2/26

• TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan

2015/2/20

• Novel Anti-epileptic Drug E Keppra® Approved in Japan for Additional Indication as Monotherapy for Partial-onset Seizures, in Addition to Existing Indication as Adjunctive Therapy for These Seizures

2015/2/20

• New UL・OS Facial and Body Wipes

2015/2/18

• Supporting Tokyo Marathon Runners with Beverages and Nutrition Before, During, and After the Race

2015/2/2

• Otsuka Pharmaceutical Expands Overseas Distribution of ORONAMIN C DRINK
  Carbonated nutritional beverage to be produced and sold in South Korea

2015/1/27

• OTSUKA AUSTRALIA PHARMACEUTICAL PTY LTD OPENS IN AUSTRALIA

2015/1/8

• Terminations of Otsuka’s Contract With OncoTherapy Science, Inc. on a Candidate Therapeutic Vaccine For Pancreatic Cancer and Otsuka’s Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candidate Therapeutic Vaccine, OTS102

2014

2014/12/26

• New Drug Application Approval of TAKECAB® for the treatment of Acid-related Diseases in Japan

2014/12/23

• ARIAD AND OTSUKA ANNOUNCE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR ICLUSIG® TO TREAT LEUKEMIAS IN JAPAN AND NINE OTHER ASIAN COUNTRIES

2014/12/19

• Otsuka Pharmaceutical Saga Nutraceuticals Research Institute Strengthens Focus on Sports Nutrition Completion of New Artificial Environment Control Room

2014/12/18

• Otsuka Pharmaceutical Acquired US-based FoodState Inc.
  Growing Supplement Business Through New Channels

2014/12/11

• OTSUKA AND LUNDBECK’S BREXPIPRAZOLE DEMONSTRATES STATISTICALLY SIGNIFICANT EFFECTS IN NEW PHASE III STUDIES IN ADULT PATIENTS WITH SCHIZOPHRENIA PRESENTED AT THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING

2014/12/10

• OTSUKA AND LUNDBECK PRESENT PHASE III DATA ON BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN ADULT PATIENTS WITH MAJOR DEPRESSION AT THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING

2014/12/8

• U.S. FDA Approves The Labeling Update Of Abilify Maintena® (Aripiprazole) For Extended-Release Injectable Suspension To Describe New Clinical Data For The Treatment Of Acutely Relapsed Adults With Schizopherenia

2014/12/2

• OTSUKA PHARMACEUTICAL TO ACQUIRE AVANIR PHARMACEUTICALS
  Full-scale entry to neurologic diseases area widens core business presence in CNS (420KB)

2014/11/28

• L-Cartin® FF Tablets For Carnitine Deficiencies To Be Introduced in Japan on December 5 Active Ingredient Carnitine in Free Form (FF) to Address the Needs of Medical Field

2014/11/21

• Nutrition & Santé Inaugurates New Factory Expanding Production Base of the French Leader in Functional and Dietetic Foods

2014/11/14

• Otsuka Group Establishes New Company in order to strengthen presence in vending machine market

2014/10/27

• New product for Japanese women
  Nature Made Fish Oil Pearl
  Small Pearl-shaped Capsules Concentrated With Essential Nutritional Balance of Fish Oil

2014/10/14

• Otsuka Pharmaceutical’s QuickNavi-Flu Influenza Diagnostic Kit to Provide Additional Diagnosis-Related Information

2014/10/1

• Calorie Mate Recipient of
  “G Mark” Good Design Long Life Design Award

2014/9/24

• U.S. FDA ACCEPTS OTSUKA AND LUNDBECK’S FILING FOR REVIEW OF BREXPIPRAZOLE FOR THE TREATMENT OF SCHIZOPHRENIA AND AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF MAJOR DEPRESSION

2014/9/16

• Otsuka Pharmaceutical Launches “Next Generation Athlete Development Project” at the 17th Asian Games Junior athletes experience world-class atmosphere at Asia’s largest competition

2014/9/16

• A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Approval in Japan for Otsuka’s Major BCR-ABL mRNA Measurement Kit

2014/9/11

• New “Plain” Flavor Calorie Mate Block
  First simple, unadorned flavor marks a return to Calorie Mate origins after 32 years

2014/9/9

• New SoyCarat Chili Pepper Flavor
  Spicy version of healthy, low GI soy snack packs grown-up appeal

2014/9/8

• New Antituberculosis Drug　Deltyba® in 50 mg Tablets, Available to Patients in Japan Starting September 26

2014/8/28

• Acquisition of Jasmine, Leading Brazilian Health Food Company

2014/8/6

• UL･OS Announces New Skin Conditioner
  Promoting the Habit of Skin Care for Middle-Aged Men

2014/8/5

• Otsuka Welfare Clinic for Refugees in Pakistan Awarded Foreign Minister's Commendation

2014/8/4

• E Keppra® 500 mg Injectable For Monotherapy Treatment of Epilepsy Submitted For Regulatory Review in Japan

2014/7/14

• OTSUKA AND LUNDBECK SUBMIT NEW DRUG APPLICATION IN THE US FOR BREXPIPRAZOLE FOR THE TREATMENT OF SCHIZOPHRENIA AND AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

2014/7/4

• After 40 Years, A New Drug For The Treatment Of Tuberculosis In Japan Deltyba® (delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)

2014/7/4

• E Keppra® Injectable Receives Marketing Authorization in Japan Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged Four and Over

2014/6/27

• Regulatory Approval Received in Japan For L-Cartin FF Tablets 100 mg・250 mg Doses That Incorporate Carnitine in Free Form

2014/6/20

• Meptin®, a Fast-acting Bronchodilator to Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin® Swinghaler® 10μg 100 Puffs

2014/5/23

• Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD), an Orphan Disease

2014/5/20

• Otsuka Pharmaceutical Named the Major Official Sponsor of Inter-High School Athletic Championships for Two Consecutive Years Special Website Features Fan-produced Support Movies and First Streaming Broadcast of All Competitions

2014/5/15

• Otsuka’s POCARI SWEAT Aims the Very First Moon Landing
  Private Firms Take the Lead in the Start of “LUNAR DREAM CAPSULE PROJECT”
  Delivering all children’s dreams 380,000KM to the moon

2014/4/30

• Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)

2014/4/9

• New SOYJOY Almond & Chocolate
  Combines Crunchy Almonds, Subtly Sweet Chocolate and the Goodness of Soy The Perfect Snack for Busy Business People

2014/4/1

• POCARI SWEAT ION WATER
  First Overseas Distribution Launched by King Car Otsuka in Taiwan

2014/4/1

• “QuickNavi Strep A” April 14 Market Launch in Japan Test Kit for the Rapid Detection of Group A Beta-hemolytic Streptococcal Antige

2014/3/31

• Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen® From Eisai (U.S.)

2014/3/27

• Otsuka and Takeda Annouce a Co-promotion Agreement in Japan of TAK-438 for the Treatment of Acid-related Diseases in the Gastrointestinal Therapeutic Area

2014/3/26

• IBM and Otsuka Develop Transformative Care Coordination Solution

2014/3/24

• Otsuka Pharmaceutical’s Samsca® Approved in Japan as the World’s First Drug Therapy for ADPKD, a Rare Kidney Disease

2014/3/17

• On April 7, Otsuka Pharmaceutical Will Launch in Japan the Number-One Diet Food Product in France, “Milical”

2014/3/13

• Launch of EQUELLE
  Equol-containing food derived from soybeans A new option for women’s health who are 40 and over during and after menopause

2014/3/7

• Anti-Epileptic Drug E Keppra Filed in Japan for Additional Indication of Monotherapy for Partial-Onset Seizures

2014/3/4

• Otsuka Pharmaceutical Opens a Second Day Care Center – the “Beanstalk Kids Center OSAKA” – at Otsuka’s New Office Building in Osaka

2014/3/4

• Otsuka Pharmaceutical was Awarded “Diversity Management Selection 100” from the Japan Ministry of Economy, Trade and Industry

2014/2/28

• Agreement to Review Memorandum of Understanding Between Otsuka Pharmaceutical and the Ministry of Health and Welfare of South Korea

2014/2/25

• Otsuka's Antipsychotic Aripiprazole Awarded the 60th Okochi Memorial Prize

2014/2/24

• Otsuka Pharmaceutical Supports the Tokyo Marathon 2014 Runners With Amino Value, the Official Beverage

2014/2/17

• Meptin Swinghaler, Easy-to-inhale Bronchodilator for COPD and Asthma Patients, Approved in Japan

2014/2/13

• Otsuka and Lundbeck announce Once-Monthly Abilify Maintena™ Approved in Canada for the Maintenance Treatment of Schizophrenia in Stabilized Adult Patients

2014/1/24

• Otsuka and Lundbeck to present new data on brexpiprazole in major depressive disorder (MDD) at European Psychiatry Association 2014 Congress

2014/1/20

• Otsuka Pharmaceutical's POCARI SWEAT to Be Official Drink for Two Consecutive Asian Games

2014/1/15

• Otsuka Pharmaceutical Submits Marketing Authorization Application in Japan for Abilify Once-Monthly Injectable Form for the Treatment of Schizophrenia

2013

2013/12/27

• European Medicines Agency (EMA) Accepts Otsuka's Marketing Authorisation Application (MAA) for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

2013/12/11

• Lundbeck and Otsuka to Co-Develop a Vaccine, Lu AF20513, Their Third Collaborative Development Project to Tackle Alzheimer’s Disease

2013/12/4

• Providing Free Health Care to Over 700,000 Afghan Refugees The 10th Anniversary of the “Otsuka Welfare Clinic”

2013/11/25

• CHMP Recommends Otsuka’s Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)

2013/11/25

• New From the US, A Smart New Way to Take Vitamin and Mineral Supplements VitaMelts® Dissolve Smoothly Without Water Available at Convenience Stores Throughout Japan From November 25

2013/11/21

• Otsuka and Lundbeck's Once-Monthly Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole

2013/10/31

• Otsuka Named as Lundbeck's Partner in Japan on Nalmefene for the Reduction of Alcohol Consumption

2013/10/23

• Get the Dietary Fiber That is Missing From Your Diet*1 With a Healthy Combination of Cereal Grains Otsuka Launches the New Products “Gerblé Multicereal Chocolate” and “Gerblé Multicereal Apricot”

2013/10/10

• Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-On Treatment for Alzheimer's Disease

2013/10/1

• Otsuka Pharmaceutical Receives the 2013 Good Design Award for the Antiplatelet Drug “Pletaal® OD Tablets”

2013/9/20

• OTSUKA AND LUNDBECK RECEIVE POSITIVE CHMP OPINION IN EUROPE FOR ABILIFY MAINTENA™, A ONCE-MONTHLY INJECTABLE FOR SCHIZOPHRENIA

2013/9/18

• Two New Flavors of SoyCarat
  Nori & Natto and Olive Oil & Garlic Flavors Debut October 2

2013/9/17

• Vasopressin V2 Receptor Antagonist Samsca®7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis

2013/9/5

• UL•OS Line of Men’s Skin Care Marks 5th Anniversary Now Effective in Minimizing the Appearance of Fine Lines and Wrinkles Caused by Dryness

2013/8/30

• Otsuka Receives Complete Response Letter from U.S. Food and Drug Administration for Tolvaptan for Use in Patients with Autosomal Dominant Polycystic Kidney Disease

2013/8/28

• Japan’s First Dry Syrup Formulation of an Anti-epileptic Drug for the Treatment of Partial-onset Seizures, E Keppra® Dry Syrup 50%, to Be Launched on August 29

2013/8/19

• On September 1, Otsuka Launches “Omugi Seikatsu”, a Healthy Breakfast Food with Barley Beta-Glucans

2013/8/6

• U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee Recommends Not to Approve Otsuka Pharmaceutical’s Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

2013/8/6

• Fingraph®, a Fingertip Blood Sampler that Conveniently Measures Sodium and Potassium Electrolytes in Just One Minute, Debuts in Japan on August 6

2013/7/26

• Otsuka Receives Opinion from CHMP on Delamanid

2013/7/17

• Lundbeck and Otsuka present data at Alzheimer’s Association International Conference 2013

2013/7/10

• Otsuka Europe Development and Commercialisation Ltd., a New Company for the Development of Pharmaceuticals Opens in the UK

2013/6/28

• Two New Formulations of E Keppra® Developed Dry Syrup Obtains Approval; Application Filed for Injectable Formulation Address various needs of patients with epilepsy from 4 years of age and contribute to improvement of compliance with medication

2013/6/14

• A New Choice of Therapy for the Treatment of Depression:
  ABILIFY® Granted Additional Approval as Adjunctive Therapy for the Treatment of Depression in Japan

2013/6/10

• The No.1 pharmacist-recommended supplement*1「Nature Made」
  The First Supplement Facility was Built in Alabama*2.
  Production Capacity Increases 40% by 2014

2013/6/7

• Otsuka has been selected by METI as a model enterprise for business continuity management

2013/6/3

• Otsuka Pharmaceutical Submits New Drug Application in Japan for Tolvaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

2013/6/3

• Vasopressin V2 Receptor Antagonist Samsca® 7.5mg Tablets To Be Launched in Japan on June 4 – Additional Choice of Dose for the Treatment of Volume Overload in Patients with Heart Failure

2013/5/31

• AntiEpileptic Drug E Keppra® Table Approved in Japan for Pediatric Epilepsy (Partial-Onset Seizures)

2013/5/22

• Study Shows Effects of Treatment with ABILIFY MAINTENA™ (Aripiprazole) on Psychiatric Hospitalization Rates for Patients with Schizophrenia

2013/5/9

• Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting

2013/4/30

• Otsuka Pharmaceutical’s 44-member Employee Dance Group “Otsuka-Ren” Presented Traditional “Awa-Odori” of Tokushima, Where the Company Originates From, At Copenhagen Sakura Festival Held in Denmark

2013/4/17

• “Epi Diary” – An Epilepsy Diary Application for iOS A New Communication Tool for Patients with Epilepsy and their Physicians Now Available at
  https://itunes.apple.com/app/epi-diary/id616736809?Is=1&mt=8

2013/4/12

• OTSUKA’S NEW DRUG APPLICATION FOR TOLVAPTAN, THE INVESTIGATIONAL COMPOUND FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD), ACCEPTED FOR REVIEW BY THE US FOOD AND DRUG ADMINISTRATION (FDA)

2013/4/4

• New Version of Pocari Sweat　Low calorie beverage with subtle sweetness, refreshing after-taste
  Pocari Sweat Ion Water　Debuts April 8, 2013

2013/4/1

• Like Having Everything At Your Fingertips? Then Check This Out!
  Otsuka Pharmaceutical Announces A Revamped Website
  April 1, 2013
  http://www.otsuka.co.jp/
  

2013/3/27

• Otsuka’s Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Filed in Japan After Half-A-Century Since Last Drug Approval for Tuberculosis

2013/3/26

• Lundbeck and Otsuka Further Expand Alliance and Enter Into Collaboration For the Development and Commercialization of Lu AE58054 in Development For Alzheimer’s Disease

2013/3/25

• Otsuka Obtains Marketing Approval in Japan for Onglyza® Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin

2013/3/14

• “Weight Management with Chocolate” White Chocolate and Orange Chocolate Gerlinéa Meal Replacement Bars Debut on March 18

2013/3/13

• The healthy benefits of whole soy flavored with crunchy peanuts SOYJOY Peanuts Debuts April 24

2013/3/7

• Otsuka Advancing Rapidly in Central Nervous System Disorders; Expanding Its Existing Collaboration with Lundbeck

2013/3/1

• FDA Approves Once-Monthly ABILIFY MAINTENA™ (Aripiprazole) for Extended-Release Injectable Suspension for the　Treatment of Schizophrenia

2013/2/22

• The First Transdermal Dopamin Agonist in Japan, Neupro® Patch, For Both Parkinson’s Disease and Restless Legs Syndrome, To Be Launched on February 26

2013/2/22

• L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg
  Two New Drug Forms for Carnitine Deficiency To Be Launched on February 26

2013/2/20

• Otsuka Pharmaceutical Contributes to the Success and Development of the Tokyo Marathon as a Total Health Care Company
  Supporting Safe Running and Encouraging Runners to Complete the Full Distance with Amino Acids, Fluids and Electrolytes

2013/2/8

• 7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Receptor Antagonist

2013/2/6

• The European Medicines Agency (EMA) approves ABILIFY® (aripiprazole) for the treatment of moderate to severe manic episodes of Bipolar I Disorder in adolescents.

2013/1/28

• UL･OS Line of Men’s Skincare Launches New SPF 50 & SPF 25 Sunscreens Applies Smoothly, Leaves No White Residue

2013/1/11

• Otsuka Pharmaceutical Files for Application of New Dry Powder Inhaler Product from the Meptin Brand

2013/1/9

• French subsidiary Nutrition & Santé acquires gluten-free nutrition company from Lactalis Group

2012

2012/12/25

• L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg
  Two New Drug Forms approved for Carnitine Deficiency

2012/12/25

• The World’s Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson’s Disease and Restless Legs Syndrome

2012/12/25

• Otsuka and Lundbeck initiate the regulatory process for aripiprazole (once-monthly) depot formulation in Europe

2012/11/20

• Official Sponsor of Osaka Marathon for Second Consecutive Year Otsuka Pharmaceutical Will Continue to Support Safe Running and Encourage Runners to Complete the Full Distance

2012/11/6

• Otsuka Pharmaceutical and Abdi Ibrahim Established a Joint Venture Company for Pharmaceutical Sales in Turkey

2012/11/5

• Otsuka Pharmaceutical Tokushima Itano Factory to Cosponsor Asan Walking Festival in Itano A Portion of Entry Fees to be Donated to Great East Japan Earthquake Relief Efforts

2012/11/5

• Otsuka's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clinical Trial

2012/10/29

• Kenja no Shokutaku Double Support
  Food for Specified Health Use with Dual Function Suppressing the Absorption of Both Sugars and Lipids, to Launch in Japan for the First Time

2012/10/1

• Super Vitamin D, Containing the Daily Optimum Dose of Vitamin D in One Single Tablet Launched from Nature Made®
  - America’s Number One Dietary Supplement Brand

2012/9/24

• New “Poppy Seed & Lemon” from Gerblé to launch on October 15
  The No.1 French Health Food Brand now in 3,000 stores nationwide

2012/9/14

• Kyowa Hakko Kirin Returns To Otsuka Pharmaceutical the Rights to Develop and Market Busulfex®, for Use As a Part of Conditioning Regimen Prior to Hematopoietic Progenitor Cell Transplantation, in Japan and in Asian Countries & Regions

2012/9/3

• ABILIFY® ,The First Antipsychotic Agent in Japan
  Applying for Adjunctive Treatment in Major Depressive Disorder

2012/8/29

• Otsuka, the First Pharmaceutical Company in Japan to Have Been Certified for “ISO22301”, the International Standard for Business Continuity Management

2012/8/1

• Vasopressin V2-Receptor Antagonist, Samsca® Tablets were Filed Additional Indication of the Treatment of Fluid Retention Associated with Cirrhosis of the Liver

2012/8/1

• Pocari Sweat Launches in Vietnam through New Joint Venture Company.
  Vietnam Launch is the 17th Market in the World Where the Pocari Sweat is Sold

2012/7/30

• Otsuka Pharmaceutical × Nakacho, Tokushima Prefecture Largest Free Live Music Concert in Japan to Be Held

2012/7/19

• Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome

2012/7/19

• Otsuka Pharmaceutical To Boost Production Capacity and Increase Sales with Third Pocari Sweat Plant in Guandong Province,China

2012/7/6

• Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd.
  Announce Worldwide Agreement to Develop Novel Digital Health Products

2012/6/29

• Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology

2012/6/26

• Reverse Daylight Savings Program to Shift Peak Energy Consumption

2012/6/21

• UCB Japan Files for Indication of Pediatric Epilepsy (Partial Onset Seizures) for E Keppra® Tablet; New Dry Syrup Formulation Filed at the Same Time

2012/6/14

• Otsuka Pharmaceutical to Participate as Core Partner in TEDxTokyo 2012 to Connect Innovative Ideas to the Future
  

2012/6/7

• The New England Journal of Medicine Publishes Efficacy Results of Otsuka’s Delamanid for Multidrug-Resistant Tuberculosis　New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months

2012/5/8

• The Federal Circuit Decision Affirming the Validity of the Asserted Claims of Otsuka’s Patent to ABILIFY®

2012/5/8

• Results from a Phase 3 Study of Once-monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting

2012/4/17

• New Antipsychotic Agent "ABILIFY® OD Tablets"
  Pursues Agreeability for Patients, Enables easy Adherence

2012/3/27

• Gerlinéa to Launch Nationwide
  −Enjoyable Calorie Control without Giving Up Sweetness−

2012/3/16

• Breaking Conventional Rules of Snack Foods, Healthy and Innovative Soy Snack "SoyCarat" Debuts

2012/3/13

• Otsuka America Announces Personnel Changes (182KB)

2012/3/5

• Otsuka Pharmaceutical Releases its UL・OS Brand of Men’s Cosmetics in South Korea First overseas market for the brand after it was launched in Japan three and a half years ago

2012/2/27

• Otsuka Pharmaceutical Supports the Tokyo Marathon for Six Years Running with Amino-Value Supporting the efforts of over 200,000 runners

2012/2/10

• Heartful Kawauchi Co., Ltd., A Promoter of Employment for Persons with Disabilities, Receives Authorization as Special Subsidiary Company

2012/2/1

• Otsuka Pharmaceutical’s Fukuroi Factory Receives FY2011 METI Minister Award for Factories Making an Outstanding Contribution to the Environment

2012/1/18

• Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets"

2012/1/13

• Otsuka Pharmaceutical Files New Drug Application for The Dopamine Agonist Transdermal Patch, Rotigotine Patch, in Japan

2012/1/13

• Otsuka Pharmaceutical and UCB focus collaboration in the area of Central Nervous System (CNS) disorders

2012/1/5

• Mucosta® ophthalmic suspension UD2% releases on January 5, 2012

2011

2011/12/14

• Otsuka Pharmaceutical Appoints New Director on Board

2011/12/7

• Otsuka Welfare Clinic awarded special commendation
  by the Ambassador of Japan in Pakistan
  Otsuka Welfare Clinic recognized for providing treatment over the past eight years to Afghan refugees in Pakistan

2011/12/1

• Survey of bowel movements and fiber intake among children Approximately 40% of elementary school children do not have daily bowel movements Approximately 60% of mothers in this group feel their children lack fiber

2011/11/22

• NEW DRUG APPLICATION FOR OTSUKA’S ONCE-MONTHLY ARIPIPRAZOLE DEPOT FORMULATION FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH SCHIZOPHRENIA ACCEPTED FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION

2011/11/21

• Streptococcus pneumoniae Kit “RAPIRUN S. pneumoniae HS (otitis media/sinusitis)” as in vitro diagnostic releases on December 1

2011/11/14

• Tokushima Itano Factory jointly Sponsors Asan Walking Festival in Itano and Appeals for the Importance of Environmental Protection and Health

2011/11/11

• OTSUKA PHARMACEUTICAL CO., LTD. AND H. LUNDBECK A/S Sign Historic Agreement to Deliver Innovative Medicines with Focus on Psychiatric Disorders Worldwide

2011/11/8

• Results of two trials show a rapid and sustained response with certolizumab pegol for treatment of rheumatoid arthritis (J-RAPID and HIKARI Studies) released at 2011 meeting of American College of Rheumatology (ACR)

2011/10/31

• Amino-Value Used as the Official Drink of the Osaka Marathon 2011 Otsuka Pharmaceutical is Now Supporting Two of Japan’s Largest Civic Marathons Amidst an Unprecedented Boom in Popularity in Japan

2011/10/20

• Otsuka Pharmaceutical Confirmed Clinical Efficacy of Rotigotine Transdermal System for Restless Legs Syndrome in Phase III Clinical Study in Japan

2011/9/15

• ～Easy Meal Replacement for Calorie Control ～
  No. 1* French Diet Food Market Brand Gerlinéa Launches Cereal Bar in Chocolate and Vanilla Flavors

2011/9/15

• Low-GI biscuit packed with fiber and bursting with five-grain cereal crunch Gérble GLUCOSANTE Launches on October 3

2011/9/8

• Healthy hair begins with a healthy scalp. Start your care routine from the scalp with UL･OS.
  UL・OS Scalp Shampoo（Medicated Cosmetic）Launches on September 13

2011/9/7

• Notice Regarding Change of Director on Board

2011/9/4

• Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye

2011/9/3

• Deliver moisture into skin UL･OS Men's Skin Care Line from Otsuka Pharmaceutical Debuts September 9, 2008

2011/8/31

• How much exercise intensity does trail walking in the mountains place on middle-aged and elderly people? Mountain climbing research suggests possibility of BCAA supplementation having "muscle fatigue inhibitory effect"

2011/8/31

• The Core of Globally Expanding Drug Discovery Research 10th Research Center wins the "Nikkei New Office Promotion Award" The Creativity-producing Office Space is Evaluated

2011/8/15

• 25,000 People Gather in Hilly Town of 10,000 for Free Live Concert Held at Tokushima Wajiki Factory Event Dedicated to Vitalization of Local Community

2011/8/8

• Otsuka Pharmaceutical Establishes Special Subsidiary Company, Heartful Kawauchi Co., Ltd., in Tokushima City to Promote Employment of Persons with Disabilities

2011/8/8

• In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' is Covered under Japanese Insurance Program, effective as of August.

2011/7/25

• Partner Agreement Concluded
  between WASEDA University Athletic Center and Otsuka Pharmaceutical

2011/6/24

• The IFPMA Welcomes Otsuka Pharmaceutical as New Member to advance Global Health

2011/6/17

• Otsuka Pharmaceutical Appoints Two Female Operating Officers for the First Time in the History of Its Pharmaceutical Business

2011/6/17

• Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors

2011/6/16

• Anti-cancer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (dasatinib)" approved as the first-line treatment of chronic myeloid leukemia

2011/6/15

• Otsuka receives approval for Streptococcus pneumoniae Kit “RAPIRUN S. pneumoniae HS (otitis media/sinusitis)” as in vitro diagnostic on June 13

2011/6/8

• Otsuka Pharmaceutical confirmed clinical efficacy of rotigotine trandermal system in Phase III clinical study in patients with advanced Parkinson's disease in Japan

2011/5/24

• America's Number One-selling Vitamin, Mineral and Supplement Brand Five Years Running - Nature Made New Series Providing Nutritional Support in a Single Pill Taken Daily Super Multiple Vitamin & Minerals and Super Fish Oil Set for June 6 Release

2011/5/23

• Oronamin-C Drink
  First Small-Volume Vitamin Drink in Japan to Exceed 30 Billion Bottles in Accumulated Sales

2011/5/19

• Gerlinéa, the No. 1 brand for French Diet Food market
  ～Easy and Enjoyment; French Style Calorie Control～
  Test Marketing Begins June 2, 2011 in Shizuoka and Tokyo

2011/5/17

• Otsuka Pharmaceutical Establishes Subsidiary, Otsuka SA, to Facilitate Public Advocacy for the Company’s Global Tuberculosis Program

2011/5/16

• OTSUKA PHARMACEUTICAL CO., LTD. ANNOUNCES RESULTS FROM A PHASE 2 STUDY OF INVESTIGATIONAL PRODUCT OPC-34712 AS ADJUNCTIVE THERAPY IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

2011/5/6

• Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced at ARVO 2011

2011/4/14

• Handy Skin Care for Active Men
  UL・OS Refresh Sheet (Medicated Cosmetic) Launches on April 21

2011/3/10

• Otsuka Pharmaceutical Received Approval for Additional Indication of L-Cartin® tablets for Carnitine Deficiency in Japan

2011/3/7

• Otsuka Pharmaceutical Announces Changes to Board Members

2011/3/7

• SOYJOY Fruity Tomato, a New Combination of Soy and Tomato, Launches on April 11

2011/2/18

• ABILIFY®(aripiprazole) Approved for Maintenance Treatment of Bipolar I Disorder as an Adjunct to Either Lithium or Valproate

2011/2/17

• Tokushima Itano Factory Awarded
  "Excellent Energy Management Factory" Commendation from
  Chief of Shikoku Bureau of Economy, Trade and Industry
  Achieves roughly 3.5% reduction in energy consumption efficiency unit

2011/2/16

• In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes

2011/2/16

• Otsuka Foods and Otsuka Pharmaceutical to Partner with ITO EN
  on Cross-Sales of Products in Vending Machines

2011/2/2

• Sparkling Soy Water SOYSH
  Internet Buzz Leads to Its Distribution to Stores Nationwide in Japan Starting March 14, 2011

2011/2/1

• Otsuka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101

2011/1/31

• Nutraceutical Business in Europe Moves to New Stage SOYJOY, the First Japanese Product, Set to Debut in 4 Countries

2011/1/24

• Otsuka Pharmaceutical Files for Additional Indication Regulatory Approval in Japan for ABILIFY®, a Treatment for the Manic Symptoms Associated with Bipolar Disorder

2011/1/20

• Amino-Value set to be the Official Drink of the Tokyo Marathon 2011 Support to Range from Training to Race Day

2010

2010/12/21

• Starting co-promotion of the anti-cancer agent “SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg” (dasatinib) in Japan

2010/12/17

• The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL®(dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.

2010/12/10

• World's First Aquaretic Agent for the Treatment of Volume Overload in Patients with Heart Failure
  Samsca® Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, to be Launched in Japan on December 14

2010/12/9

• Tokushima Itano Factory
  Recognized Among "Corporate Greening Linked to Conservation of Biodiversity: Best 100"
  Sole factory manufacturing medical-use pharmaceuticals to receive recognition
  

2010/12/7

• Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data

2010/11/19

• Toward a Factory that is Friendly to Both the Environment and People the Tokushima Itano Factory Helps to Support the Asan Earth Festival in Itano to be Held on November 23, 2010

2010/11/18

• Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain

2010/11/16

• Otsuka Prevails in U.S. Abilify® Patent Litigation

2010/11/11

• Clinical tests in Japan demonstrate research results relating to the efficacy of "Ion supply drink" for dehydration after bathing

2010/11/9

• Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta® Ophthalmic Suspension for Dry Eye

2010/11/1

• FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase

2010/10/27

• SAMSCA™ Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, Receive Regulatory Approval in Japan

2010/10/25

• New Release of Medicated Skin Wash in 500mL Pump-style Economy Size and Refill Pouch Available from November 12, 2010

2010/10/6

• OTSUKA ANNOUNCES PHASE 3 ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT TRIAL INTERIM ANALYSIS REVEALS EFFICACY CRITERIA MET

2010/10/5

• OTSUKA OPENS FIRST OFFICE IN CANADA
  Important Milestone for Growing North American Pharmaceutical Operations

2010/9/29

• Tweet Runners app for iPhone released on September 29th
  Tweet Runners and Amino-Value keep runners going

2010/9/28

• Otsuka Pharmaceutical and Acucela Enter New Co-Development and
  Co-Promotion Agreement for OPA-6566 for Glaucoma

2010/9/17

• Antiepileptic Drug 'E Keppra® Tablet' with New Mechanism of Action
  Released on September 17

2010/9/13

• The Results of CSPS 2, a Large-scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Published in The Lancet Neurology Online

2010/9/8

• Renewed Package Design for Nature Made
  America's number one-selling vitamin, mineral and supplement brand

2010/9/1

• Construction of 'OPS-5', New Plant to Manufacture Active Pharmaceutical Ingredients in Saga Factory Completed on September 1

2010/8/31

• Publication of Environmental and Social Report 2010
  - Featuring approaches to help build a low-carbon, recycling-oriented society, development of environment-conscious products and social action programs -

2010/8/16

• 21st Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki '10 on August 13, 2010

2010/7/23

• E Keppra® (levetiracetam) receives regulatory approval in Japan

2010/7/12

• SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase

2010/6/30

• GW and Otsuka Agree Three Year Extension
  to Global Cannabinoid Research Collaboration

2010/6/14

• Otsuka receives approval for Rapirun® H. Pylori Antibody Stick as in vitro diagnostic device on June 8, 2010

2010/6/10

• Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF:39KB)

2010/6/9

• Four-Year Follow-Up Data for SPRYCEL® (dasatinib)Demonstrate 82 Percent Overall Survival
  in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®

2010/6/8

• SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic
  Response Rates Compared to Gleevec® in Study of Adult Patients with Newly Diagnosed
  Chronic Myeloid Leukemia in Chronic Phase

2010/5/31

• Streptococcus pneumoniae Kit "RAPIRUN Pneumococcus" Approval obtained as in vitro diagnostic on May 26

2010/3/31

• First reader-participation collaboration
  OTSUKA Health Comic Library Sequel Vol. 3
  “We Are Children of the Earth: The Environment & Our Health”
  March 31 publication for donation to elementary schools nationwide
  

2010/3/17

• Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD

2010/3/12

• FerriSeltz® powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancreatography

2010/3/11

• Rapid Assay Kit for RS virus, QUICKNAVI™-RSV, Launch on April 6

2010/3/8

• In-vitro Diagnostic Kit, WT1 mRNA Assay Kit "Otsuka" Application Filed for Additional Purpose of Use with Myelodysplastic Syndromes

2010/3/5

• New Medicated Skin Wash from UL･OS Line of Men's Face & Body Care Available from April 22, 2010

2010/3/1

• The Results of CSPS II, a Large-scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Presented at American Stroke Association's International Stroke Conference on February 26

2010/2/25

• French Health Food Brand Gerblé to Debut in Japan Made from rigorously selected natural ingredients in southern France Test Marketing Begins April 6, 2010

2010/1/28

• InnerSignal UV Protect Make-up Base b Will Be Launched on March 1, 2010

2010/1/26

• Otsuka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic Cancer Vaccine, OTS102

2009

2009/12/2

• Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration

2009/11/25

• U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)

2009/9/8

• New addition to CalorieMate® line of balanced nutrition blocks CalorieMate® Block, Maple Flavor First new flavor in two years debuts September 29

2009/8/26

• New SOYJOY Favored with Blueberries and White Chocolate Chips SOYJOY Blueberry Debuts September 29, 2009

2009/8/17

• Otsuka Pharmaceutical Supports 8th Annual Wheelchair Basketball Camp in Ibaraki held from August 14-16, 2009

2009/8/14

• 20th Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki ’09 on August 13, 2009

2009/8/4

• The European Commission Approves SAMSCA™ (tolvaptan), Europe’s First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH).

2009/7/13

• Pocari Sweat in 900ml PET Eco-bottles New lightweight eco-bottles achieve 30% reduction in packaging weight

2009/6/19

• Fiscal Year through March 2009 Non-consolidated Results of Otsuka Pharmaceutical Co., Ltd. (PDF:314KB)

2009/6/19

• Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF:162KB)

2009/5/21

• FDA Approves SAMSCA™ (tolvaptan), The First and Only Oral Vasopressin Antagonist to Treat Patients with Clinically Significant Hypervolemic and Euvolemic Hyponatremia

2009/4/6

• Otsuka and Bristol-Myers Squibb Extend U.S. Agreement for ABILIFY and Establish a Global Oncology Collaboration

2009/4/6

• Otsuka Pharmaceutical Special Sponsorship Pocari Sweat U-12 Soccer League

2009/3/31

• 20th Anniversary Edition Published March 31 OTSUKA Health Comic Library Sequel Vol. 2 "Explore! All About Our Bodies" Educational comic series donated to elementary schools nationwide

2009/3/26

• Make-up removers formulated with moisturizing ingredient AMP expand the InnerSignal line of skin care products gentle, thorough removal of sebum and makeup

2009/3/25

• Antipsychotic agent ABILIFYR Oral Solution 0.1% to be Launched on April 10, 2009 in Japan

2009/3/12

• Otsuka Pharmaceutical Supports Anti-Doping Efforts through Participation in “Sports Pharmacist” Project

2009/2/26

• Third product in fruit soy bar SOYJOY ‘Plus’ series SOYJOY Banana Calcium Plus Debuts April 1, 2009

2009/2/25

• Produced by Amino-Value “Virtual Tokyo Marathon 2009” Select your favorite avatar and challenge the 42.195km run

2009/1/30

• Otsuka Pharmaceutical Established Otsuka Shanghai Research Institute in China for Innovative Drug Discovery Research

2009/1/29

• UL・OS Line of Men's Skincare Launches Sunscreen Formulated with Moisturizing Ingredient AMP Initial launch in Kyushu and Okinawa, February 9

2008

2008/12/24

• Otsuka Pharmaceutical Co., Ltd. to acquire Nutrition & Sante, the European market leader in functional and dietetic foods

2008/11/20

• Amino-Value Supports Tokyo Marathon 2009 as Official Drink BCAA Beverage to be Supplied as Support for 35,000 Runners

2008/10/6

• Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration

2008/9/4

• Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye

2008/9/4

• Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration

2008/9/3

• Deliver moisture into skin
  UL•OS Men's Skin Care Line from Otsuka Pharmaceutical
  Debuts September 9, 2008

2008/8/28

• New addition to fruit soy bar SOYJOY 'plus' series lineup
  SOYJOY Orange Folic Acid Plus Debuts October 1, 2008

2008/8/26

• Otsuka Pharmaceutical Co., Ltd. Makes Capital Investment to Acquire Interpharma Praha, Czech Republic